(AOF) – Novavax is expected to rise in the pre-market on Wall Street after announcing today that the European Commission has granted it marketing authorization for its Nuvaxovid Covid-19 vaccine (recombinant, with adjuvant) put updated for 2024-2025 for the prevention of COVID-19 in the European Union. This decision follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency. Novavax’s vaccine is also authorized in the United States and complies with Food and Drug Administration guidelines.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article? Share it with your friends using the buttons below.
Related News :